Bayer, J&J's heart drug Xarelto fails trial to widen use

Bayer and Johnson & Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential new patient subgroup failed to show a statistically reliant benefit.